Bristol Myers Squibb’s (BMY) Opdivo is part of the company’s alliance with Ono Pharmaceutical. Opdivo reported revenues of $1.2 billion during 2Q17, a rise of 42.0% compared to $840.0 million in 2Q16.
The above graph shows revenues for Opdivo over the last few quarters. Opdivo was the company’s largest revenue-contributing drug in 2Q17.
Uses of Opdivo
The blockbuster drug Opdivo is approved for the treatment of the following cancer patients:
- previously treated patients with advanced non-small cell lung cancer
- patients with metastatic melanoma
- previously treated patients with advanced renal cell carcinoma
- patients with squamous cell carcinoma of the head and neck that has relapsed or spread after previous treatments
- patients with classical Hodgkin’s lymphoma where the disease has relapsed after an autologous stem cell transplant and treatment with Adcetris, or where the disease has relapsed after three or more treatments including autologous stem cell transplant
- previously treated patients with advanced urothelial carcinoma
- patients with metastatic, MSI-H (microsatellite instability high) or dMMR (DNA mismatch repair) colorectal cancer that has reported progression after treatment with fluoropyrimidine, irinotecan, and oxaliplatin
Recent Opdivo developments
Recent developments for Opdivo include the following:
- On August 15, 2017, Bristol-Myers Squibb announced the results of its CheckMate 214 clinical study, a phase III study evaluating Opdivo in combination with Yervoy in poor-risk patients with previously untreated advanced or metastatic renal cell carcinoma.
- On August 1, 2017, the FDA (U.S. Food & Drug Administration) approved Opdivo for the treatment of metastatic, MSI-H, or dMMR colorectal cancer in patients reporting disease progression after treatment with fluoropyrimidine, irinotecan, and oxaliplatin. The approval was based on the CheckMate 142 study.
- On July 24, 2017, the FDA accepted the supplemental biologics application for updating the dosing of Opdivo 480 mg (milligram) to be infused over 30 minutes every four weeks for all approved monotherapy indications.
To divest the company-specific risks, investors can consider ETFs such as the Vanguard Healthcare ETF (VHT), which holds 2.8% of its total assets in Bristol-Myers Squibb (BMY). VHT also holds 4.9% in Merck & Co. (MRK), 3.3% in AbbVie (ABBV), and 2.8% in Gilead Sciences (GILD).